{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011082","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.044179+00:00","generated_at":"2026-05-24T08:42:03.533457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulmatrix reports 2024 net loss of $9.6M; proposes merger with Cullgen and asset divestment","bullets":["Net loss for 2024 of $9.6M ($2.62 per share) vs $14.1M ($3.87 per share) in 2023.","Revenues increased to $7.8M from $7.3M, driven by a contract modification with Cipla.","Cash and equivalents $9.5M; sufficient to fund operations through anticipated Merger close in H1 2025.","Proposed merger with Cullgen expected to close H1 2025; plans to divest Phase 2-ready PUR3100 and iSPERSE technology.","PUR1900 Phase 2b enrollment paused; no further financial responsibility; 2% royalties on future net sales outside U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011082","json":"https://secwatch.observer/filing/0001493152-25-011082.json","markdown":"https://secwatch.observer/filing/0001493152-25-011082.md","text":"https://secwatch.observer/filing/0001493152-25-011082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315225011082/0001493152-25-011082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315225011082/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:42:03.533457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}